Clinical trial

Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer

NCT03030131

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2017-01-12

PhasePHASE2

Study timeline

Study start (actual)2017-01-12Date precision: day

Registry last updated2023-03-14

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Carcinoma, Non-Small-Cell Lungunresolved

Interventions

DurvalumabDRUG · verified · RxNorm: durvalumab

Sponsors & collaborators

Intergroupe Francophone de Cancerologie Thoraciquelead sponsor

Mapped research locations

ParisFrance6 MarseilleFrance2 CaenFrance2 ToulouseFrance1 StrasbourgFrance1 BordeauxFrance1 NantesFrance1 Clermont-FerrandFrance1 GrenobleFrance1 Saint-HerblainFrance1 LimogesFrance1 NancyFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03030131 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.